Last reviewed · How we verify
NCT07003256
Observational Study: Romiplostim for Platelet Recovery in Haploidentical HSCT
trial testing Romiplostim in Thalassemia in Children in 30 participants. Enrolling by invitation.
30 April 2026
Quick facts
| Lead sponsor | Haikou Affiliated Hospital of Central South University Xiangya School of Medicine |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 1 September 2024 |
| Primary completion | 30 April 2026 |
| Estimated completion | 30 April 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Romiplostim (ROMIPLOSTIM) — full drug profile →
Conditions studied
- Thalassemia in Children — all drugs for Thalassemia in Children →
Sponsor
Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
Who can join
Adults 2 to 17, any sex, with Thalassemia in Children. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this observational study is to explore the long-term effects of roprastine given to promote platelet implantation in hematopoietic stem cell hemicongruent transplantation in children with thalassemia. The main questions it aimed to answer is: Is roprastine safe and effective for platelet implantation in children with thalassemia hemicongruent transplantation? Participants who have already received roprastine as part of routine medical care for hematopoietic stem cell hemicongruent transplantation in children with thalassemia will answer online survey questions about the effects of their platelet implantation within 8 weeks.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07003256
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Romiplostim
Trials testing the same drug.
- NCT07001254 — UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia · Phase 2 · not yet recruiting
- NCT07400341 — Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA · Phase 2 · recruiting
- NCT06345495 — High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly · Phase 2 · recruiting
- NCT06535685 — A Study of Romiplostim for the Treatment of Refractory Transfusion-dependent NSAA · Phase 4 · not yet recruiting
- NCT06516484 — Ropustin for Refractory Aplastic Anaemia After Radiotherapy - a Single-centre, Prospective, Open-label, Single-arm Study · Phase 4 · not yet recruiting
Other recruiting trials for Thalassemia in Children
Currently open trials in the same condition.
- NCT05426252 — Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia · Phase 1, PHASE2 · recruiting
Other Haikou Affiliated Hospital of Central South University Xiangya School of Medicine trials
Trials by the same sponsor.
- NCT07018804 — Mechanisms and Targeted Therapy of Airway Basal Cell Dysfunction in Bronchiolitis Obliterans Syndrome · NA · enrolling by invitation
- NCT07003269 — Observational Study: Hetrombopag for Platelet Recovery in Haploidentical HSCT · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07003256 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
- Last refreshed: 6 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07003256.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing